America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
**What are the potential side effects of using targeted therapies like AOH1996 compared to traditional chemotherapy?**
**Interview with Dr. Linda Malkas: Advancements in Targeted Chemotherapy for Cancer**
**Interviewer:** Good morning, Dr. Malkas. Thank you for joining us today to discuss the exciting advancements from your research team at City of Hope Hospital. Could you start by explaining what AOH1996 is and how it works?
**Dr. Malkas:** Good morning, and thank you for having me! AOH1996 is a novel molecule developed as a targeted chemotherapy drug that selectively kills cancer cells. It targets a specific variant of a protein known as PCNA, which plays a critical role in DNA replication and tumor growth. You can think of PCNA as a major airport terminal where only cancerous planes can land. AOH1996 effectively disrupts this ‘hub’, halting the growth of cancer cells while leaving normal cells largely unaffected.
**Interviewer:** That’s a captivating analogy! What types of cancers is AOH1996 effective against according to your research?
**Dr. Malkas:** In our studies, AOH1996 has shown effectiveness against a variety of solid tumors, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We’ve conducted extensive testing on over 70 cancer cell lines, and the results are promising.
**Interviewer:** You mentioned that the drug has undergone clinical research. What have the results indicated so far, and what do the next steps look like?
**Dr. Malkas:** Our findings, published in ‘Cell Chemical Biology’, demonstrated that AOH1996 specifically disrupts the cell cycle of cancer cells, leading to their destruction. The next logical step is to initiate clinical trials to assess the safety and efficacy of AOH1996 in human patients. We’re hopeful that these trials will confirm our laboratory results.
**Interviewer:** It’s incredible to see such targeted approaches in cancer treatment. What does this mean for the future of cancer therapies?
**Dr. Malkas:** Targeted therapies like AOH1996 represent a significant shift towards personalized medicine in oncology. They allow us to specifically target genetic mutations present in cancer cells, potentially leading to fewer side effects compared to traditional chemotherapy. This could usher in a new era where treatments are tailored to the individual patient, improving outcomes and quality of life.
**Interviewer:** Thank you, Dr. Malkas, for sharing these insights into your groundbreaking work. We look forward to hearing more about the clinical trials!
**Dr. Malkas:** Thank you! I appreciate the opportunity to discuss this important research.
